Health Canada approves an extended indication for Kisqali (ribociclib) in combination treatment

Novartis

16 April 2020 - Breast cancer is the most common female cancer in Canada.

Novartis Pharmaceuticals Canada is pleased to announce that Kisqali (ribociclib) is now indicated for use in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer regardless of their menopause status and in combination with various approved hormonal treatment options.

Health Canada has approved an extended indication for Kisqali: in combination with fulvestrant for the treatment of post-menopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy, as well as in combination with an aromatase inhibitor (and luteinising hormone releasing hormone agonist) for the treatment of pre/peri-menopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy.

The approval is based on results from the pivotal MONALEESA-3 and MONALEESA-7 trials.

Read Novartis press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada